Zentalis Pharmaceuticals Investor Presentation — September 2021

Document content

C O R P O R AT E P R E S E N TAT I O N

S E P T E M B E R 2 0 2 1Broad Oncology Pipeline Designed to Improve Patient Outcomes

Zentalis Pharmaceuticals, Inc.(“we,” “us,” “our,” “Zentalis” orthe“Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward -looking

statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Allstatements contained inthis presentation that donotrelate tomatters ofhistorical fact should beconsidered

forward -looking statements, including without limitation statements regarding our future financial orbusiness performance, plans, prospects, trends orstrategies, objectives ofmanagement,

competition and other financial and business matters, thepotential, safety, efficacy, and regulatory and clinical progress ofour current and prospective product candidates, plans and timing forthe

initiation ofand release ofdata from ourclinical trials and ourability tomeet other keymilestones, planned preclinical activities, ourcurrent and prospective collaborations, theestimated size ofthe

market forourproduct candidates, and thetiming and success ofourdevelopment and commercialization ofouranticipated product candidates and themarket acceptance thereof areforward -looking

statements, aswell asstatements that include thewords “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements ofafuture or

forward -looking nature .These statements areneither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results,

performance orachievements tobematerially different from anyfuture results, performance orachievements expressed orimplied bytheforward -looking statements, including, butnotlimited to,the

following :theoutbreak ofthenovel coronavirus disease, COVID -19,hasadversely impacted and may continue toadversely impact ourbusiness, including ourpreclinical studies and clinical trials ;our

limited operating history, which may make itdifficult toevaluate ourcurrent business and predict ourfuture success and viability ;wehave and expect tocontinue toincur significant losses ;ourneed for

additional funding, which may notbeavailable ;oursubstantial dependence onthesuccess ofourlead product candidate ;failure toidentify additional product candidates and develop orcommercialize

marketable products ;theearly stage ofour development efforts ;potential unforeseen events during clinical trials could cause delays orother adverse consequences ;risks relating totheregulatory

approval process orongoing regulatory obligations ;failure toobtain U.S.orinternational marketing approval ;ourproduct candidates may cause serious adverse side effects ;interim, initial, “topline”,